KR101953270B1 - 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제 - Google Patents

무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제 Download PDF

Info

Publication number
KR101953270B1
KR101953270B1 KR1020167001010A KR20167001010A KR101953270B1 KR 101953270 B1 KR101953270 B1 KR 101953270B1 KR 1020167001010 A KR1020167001010 A KR 1020167001010A KR 20167001010 A KR20167001010 A KR 20167001010A KR 101953270 B1 KR101953270 B1 KR 101953270B1
Authority
KR
South Korea
Prior art keywords
letter
amorphous
minutes
dissolution
acetonitrile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167001010A
Other languages
English (en)
Korean (ko)
Other versions
KR20160029075A (ko
Inventor
빌프리에트 슈바프
디르크 정
크리스티안 쉬카네더
벨자네 매르텐스
마카엘 리메르트
클레멘스 보테
마티아스 베르베
니콜 린데르만
Original Assignee
아이쿠리스 안티-인펙티브 큐어스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이쿠리스 안티-인펙티브 큐어스 게엠베하 filed Critical 아이쿠리스 안티-인펙티브 큐어스 게엠베하
Publication of KR20160029075A publication Critical patent/KR20160029075A/ko
Application granted granted Critical
Publication of KR101953270B1 publication Critical patent/KR101953270B1/ko
Assigned to 아이체246 아게 운트 코. 카게 reassignment 아이체246 아게 운트 코. 카게 권리의 전부이전등록 Assignors: 아이쿠리스 안티-인펙티브 큐어스 아게
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167001010A 2013-06-19 2014-06-19 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제 Active KR101953270B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP13003120.6 2013-06-19
EP13003120 2013-06-19
EP14165027.5 2014-04-16
EP14165027 2014-04-16
PCT/EP2014/062974 WO2014202737A1 (en) 2013-06-19 2014-06-19 Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration

Publications (2)

Publication Number Publication Date
KR20160029075A KR20160029075A (ko) 2016-03-14
KR101953270B1 true KR101953270B1 (ko) 2019-02-28

Family

ID=50982905

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167001010A Active KR101953270B1 (ko) 2013-06-19 2014-06-19 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제

Country Status (34)

Country Link
US (1) US10442773B2 (https=)
EP (1) EP3010891B1 (https=)
JP (2) JP6445546B2 (https=)
KR (1) KR101953270B1 (https=)
CN (2) CN120097924A (https=)
AU (1) AU2014283231B2 (https=)
BR (1) BR112015031979B1 (https=)
CA (1) CA2916143C (https=)
CU (1) CU24619B1 (https=)
CY (1) CY1121732T1 (https=)
DK (1) DK3010891T3 (https=)
DO (1) DOP2015000303A (https=)
EA (1) EA036131B1 (https=)
ES (1) ES2730958T3 (https=)
HR (1) HRP20190936T1 (https=)
HU (1) HUE043721T2 (https=)
IL (2) IL243228B (https=)
LT (1) LT3010891T (https=)
MD (1) MD4673C1 (https=)
ME (1) ME03483B (https=)
MX (1) MX373764B (https=)
MY (1) MY179502A (https=)
NZ (1) NZ715387A (https=)
PE (1) PE20160659A1 (https=)
PH (1) PH12015502821B1 (https=)
PL (1) PL3010891T3 (https=)
PT (1) PT3010891T (https=)
RS (1) RS58882B1 (https=)
SG (1) SG11201510426PA (https=)
SI (1) SI3010891T1 (https=)
SM (1) SMT201900327T1 (https=)
UA (1) UA117755C2 (https=)
WO (1) WO2014202737A1 (https=)
ZA (1) ZA201509239B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102012101673A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
JP6445546B2 (ja) * 2013-06-19 2018-12-26 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 非晶質レテルモビル及び経口投与のためのその固形医薬製剤
WO2017170858A1 (ja) 2016-03-31 2017-10-05 大日本住友製薬株式会社 溶出性に優れた経口製剤
WO2020186025A1 (en) * 2019-03-12 2020-09-17 Microbiotix, Inc. Combination drug treatment for human cytomegalovirus
CN111024861A (zh) * 2019-12-31 2020-04-17 山东省药学科学院 一种莱特莫韦及含莱特莫韦的制剂中有关物质的检测方法
EP3906929A1 (en) 2020-05-08 2021-11-10 AiCuris GmbH & Co. KG Letermovir for use in the prevention and the treatment of coronavirus infections
US20230312485A1 (en) 2020-08-17 2023-10-05 Lupin Limited A precipitation process for amorphous letermovir
EP4262805A4 (en) * 2020-12-16 2024-11-27 Merck Sharp & Dohme LLC MINI-TABLET DOSAGE FORM OF A VIRAL TERMINASE INHIBITOR AND USES THEREOF
CN115403528B (zh) * 2021-05-27 2025-01-07 南京正大天晴制药有限公司 无定形3,4-二氢喹唑啉衍生物的制备方法
AR128035A1 (es) * 2021-12-21 2024-03-20 Aic246 Ag & Co Kg Composiciones farmacéuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de potasio
CN114942278B (zh) * 2022-04-12 2023-09-08 山东诚创蓝海医药科技有限公司 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法
WO2024037485A1 (zh) * 2022-08-15 2024-02-22 上海迪赛诺化学制药有限公司 一种来特莫韦无定形的制备方法
CN116338119B (zh) * 2023-02-24 2026-03-13 重庆希韦医药科技有限公司 一种来特莫韦包合物溶液体外释放度的测定方法
WO2025133248A1 (en) 2023-12-21 2025-06-26 Aic246 Ag & Co. Kg Diastereomeric aminoalcohol and aminoether salts of 2-[(4r,s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl]acetic acid and their use for enantiomeric separation
WO2025216283A1 (ja) * 2024-04-12 2025-10-16 東和薬品株式会社 レテルモビル含有医薬組成物ならびにその製造方法および用途
CN119745803A (zh) * 2024-12-30 2025-04-04 上海奥科达医药科技股份有限公司 一种来特莫韦制剂组合物及其制备方法
CN120927867B (zh) * 2025-10-11 2026-01-06 成都诺和晟欣生物医药有限公司 一种来特莫韦注射液中对映异构体的hplc检测方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066622A1 (en) * 2003-02-12 2007-03-22 Tobias Wunberg 2-(3-Phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
US20090221822A1 (en) * 2005-06-15 2009-09-03 Bayer Healthcare Ag Process for the Preparation of Dihydroquinazolines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10319612A1 (de) * 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
EP1871345B1 (en) * 2005-04-12 2012-08-01 Elan Pharma International Limited Nanoparticulate erlotinib formulations
CN103501608A (zh) * 2011-05-04 2014-01-08 默沙东公司 药用物质、药物组合物和制备它们的方法
DE102012101673A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101659A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
WO2014047562A2 (en) * 2012-09-21 2014-03-27 Epiphany Biosciences Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain
JP6445546B2 (ja) * 2013-06-19 2018-12-26 アイキュリス アンチ−インフェクティブ キュアズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 非晶質レテルモビル及び経口投与のためのその固形医薬製剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070066622A1 (en) * 2003-02-12 2007-03-22 Tobias Wunberg 2-(3-Phenyl-2-piperazinyl-3,4-dihydroquinazolin-4-yl)acetic acids as antiviral agents, especially against cytomegaloviruses
US20090221822A1 (en) * 2005-06-15 2009-09-03 Bayer Healthcare Ag Process for the Preparation of Dihydroquinazolines

Also Published As

Publication number Publication date
CU20150179A7 (es) 2016-07-29
SG11201510426PA (en) 2016-01-28
IL263978A (en) 2019-01-31
EP3010891A1 (en) 2016-04-27
CU24619B1 (es) 2022-08-09
SI3010891T1 (sl) 2019-09-30
IL243228B (en) 2020-04-30
HUE043721T2 (hu) 2019-09-30
CN120097924A (zh) 2025-06-06
AU2014283231B2 (en) 2017-12-07
US20160145216A1 (en) 2016-05-26
MD20150126A2 (ro) 2016-06-30
MX2015017758A (es) 2016-06-21
ZA201509239B (en) 2022-03-30
BR112015031979B1 (pt) 2022-05-24
CN105555771A (zh) 2016-05-04
PT3010891T (pt) 2019-06-21
CN105555771B (zh) 2025-02-21
IL243228A0 (en) 2016-02-29
MD4673C1 (ro) 2020-11-30
HK1223935A1 (en) 2017-08-11
NZ715387A (en) 2018-02-23
LT3010891T (lt) 2019-08-26
BR112015031979A2 (pt) 2017-07-25
CA2916143C (en) 2019-01-29
JP6445546B2 (ja) 2018-12-26
SMT201900327T1 (it) 2019-07-11
RS58882B1 (sr) 2019-08-30
ME03483B (me) 2020-01-20
PH12015502821A1 (en) 2016-03-21
CA2916143A1 (en) 2014-12-24
MD4673B1 (ro) 2020-02-29
AU2014283231A1 (en) 2016-01-21
EA036131B1 (ru) 2020-10-01
JP6770035B2 (ja) 2020-10-14
EP3010891B1 (en) 2019-04-10
PH12015502821B1 (en) 2019-09-25
US10442773B2 (en) 2019-10-15
KR20160029075A (ko) 2016-03-14
DK3010891T3 (da) 2019-06-24
EA201600024A1 (ru) 2016-12-30
IL263978B (en) 2020-07-30
DOP2015000303A (es) 2016-01-15
HRP20190936T1 (hr) 2019-10-04
MY179502A (en) 2020-11-09
JP2018193401A (ja) 2018-12-06
JP2016522238A (ja) 2016-07-28
ES2730958T3 (es) 2019-11-13
BR112015031979A8 (pt) 2018-01-23
CY1121732T1 (el) 2020-07-31
MX373764B (es) 2020-03-24
PL3010891T3 (pl) 2019-11-29
UA117755C2 (uk) 2018-09-25
WO2014202737A1 (en) 2014-12-24
PE20160659A1 (es) 2016-07-24

Similar Documents

Publication Publication Date Title
KR101953270B1 (ko) 무정형 레터모비어 및 그의 경구 투여용 고체 제약 제제
EP2948141B1 (en) Pharmaceutical composition with improved bioavailability
US20210228489A1 (en) Compositions for treating cystic fibrosis
US8227463B2 (en) Amorphous body composed of heterocyclic compound, solid dispersion and pharmaceutical preparation each comprising the same, and process for production of the same
US20210069174A1 (en) Compositions and methods for treatment of cystic fibrosis
JP2021512117A (ja) 嚢胞性線維症を処置するための医薬組成物
EP2538925A2 (en) Apixaban formulations
JP2011530532A (ja) 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物
Kim et al. Development and pharmaceutical approach for sustained-released metformin succinate tablets
RU2767872C2 (ru) Фармацевтическая композиция и способ ее получения
KR102601617B1 (ko) 비-뉴클레오시드 역전사 효소 억제제의 조성물
RU2822220C9 (ru) Фармацевтические композиции для лечения муковисцидоза
RU2822220C2 (ru) Фармацевтические композиции для лечения муковисцидоза
HK1223935B (en) Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
EA043692B1 (ru) Аморфный летермовир и содержащие его твердые фармацевтические препараты, предназначенные для перорального введения
HK40045939A (en) Pharmaceutical composition with improved bioavailability

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

FPAY Annual fee payment

Payment date: 20220210

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8